

1 **Charting Elimination in the Pandemic: A SARS-CoV-2 Serosurvey of Blood Donors in**  
2 **New Zealand**

3 **Authors:** Lauren H. Carlton<sup>1</sup>, Tiffany Chen<sup>1</sup>, Alana L. Whitcombe<sup>1</sup>, Reuben McGregor<sup>1</sup>, Greg  
4 Scheurich<sup>2</sup>, Campbell R. Sheen<sup>3</sup>, James M. Dickson<sup>1</sup>, Chris Bullen<sup>1</sup>, Annie Chiang<sup>1</sup>, Daniel J.  
5 Exeter<sup>1</sup>, Janine Paynter<sup>1</sup>, Michael G. Baker<sup>4</sup>, Richard Charlewood<sup>2</sup>, Nicole J. Moreland<sup>1#</sup>

6

7 **Affiliations:**

8 <sup>1</sup>The University of Auckland, Auckland, New Zealand

9 <sup>2</sup>The New Zealand Blood Service, Auckland, New Zealand

10 <sup>3</sup>Callaghan Innovation, Christchurch, New Zealand

11 <sup>4</sup>University of Otago, Wellington, New Zealand

12 **#Corresponding Author:**

13 Associate Professor Nicole J. Moreland, Email: [n.moreland@auckland.ac.nz](mailto:n.moreland@auckland.ac.nz)

14

15 **Keywords:** SARS-CoV-2, COVID-19, serosurvey, Spike, receptor binding domain,  
16 seroprevalence, New Zealand, elimination

17

18 **Abstract**

19           A large-scale SARS-CoV-2 serosurvey of New Zealand blood donors (n=9806) was  
20 conducted at the end of 2020. Seroprevalence, after adjusting for test sensitivity and specificity,  
21 was very low (0.1%). This finding is consistent with limited community transmission and provides  
22 robust evidence to support New Zealand's successful elimination strategy for COVID-19.

## 23 **Research Letter**

24           New Zealand has a strategy of eliminating SARS-CoV-2 that has resulted in a low  
25 incidence of coronavirus-19 disease (COVID-19). The first case was reported on February 26<sup>th</sup>  
26 2020, and the country entered a strict nationwide lockdown one month later for 49 days (1).  
27 Through rigorous border control and managed isolation and quarantine facilities for new arrivals,  
28 New Zealand has since remained largely COVID-19 free. Globally, serological surveillance has  
29 been utilized throughout the pandemic to define cumulative incidence, including estimations of  
30 missed cases and/or asymptomatic infection. Due to lockdowns and movement restrictions, blood  
31 donors have been used as a sentinel population in many settings (2,3). The aim of this study was  
32 to describe the spread of SARS-CoV-2 in New Zealand via a blood donor serosurvey. Though the  
33 pandemic response has been highly effective, PCR testing was initially restricted due to limited  
34 diagnostic reagents (4) and there have been occasional border incursions and small community  
35 outbreaks, including a cluster in August 2020 with no identified link to the border.

36           Samples were collected by the New Zealand Blood Service via 9 static collection centers  
37 and 36 mobile collection services over a 4-week period (December 3<sup>rd</sup> 2020 - January 6<sup>th</sup> 2021)  
38 from individuals aged 16 to 88 years. Duplicates were removed, leaving 9,806 samples for  
39 analysis. Compared with the 2018 New Zealand census, participants were more likely to be aged  
40 40-59 years (43.3% versus 25.9%) and of European ethnicity (77.8% versus 61.0%) but had a  
41 similar proportion of females (49.1% versus 50.7%) and were geographically spread with 16 of 20  
42 district health board regions represented (Table 1 and Appendix). This study was assessed by the  
43 Health and Disability Ethics Committee, and additional consent was not required (21/CEN/21).

44           Antibodies to the Spike (S) protein and receptor-binding domain (RBD) persist for many  
45 months after infection, compared with antibodies to the nucleocapsid (N) protein (5,6), providing  
46 rationale for the use of S protein-based assays in serosurveys. The overall serological testing  
47 algorithm was optimized for specificity given the low number of reported COVID-19 cases in  
48 New Zealand (2,190 as of January 6<sup>th</sup> 2021) and the associated period prevalence of 0.04%, which  
49 limits the positive predictive value of tests with reduced specificity (7). Samples were first  
50 screened with a widely used and well-validated 2-step ELISA that comprises a single point dilution  
51 assay against the RBD followed by titration against trimeric S protein (Appendix) (8,9). Samples  
52 above the cut-off were tested on two further immunoassays – the EuroImmun SARS-CoV-2 IgG  
53 ELISA (EuroImmun AG, Lübeck, Germany) and the cPass surrogate Viral Neutralization Test  
54 (sVNT) (GenScript, New Jersey, USA) and deemed seropositive if above the cut-off on both  
55 commercial assays. Sensitivity and specificity for these assays were determined by Receiver  
56 Operator Characteristic (ROC) curves based on previous analyses (413 pre-pandemic negatives,  
57 99 PCR confirmed cases) (Appendix) (9,10).

58           Of the 9,806 samples, 18 were positive for both Spike IgG (EuroImmun) and antibodies  
59 that block the RBD-hACE-2 interaction (sVNT), with the values highly correlated  
60 (Pearson  $r$  0.7993,  $p < 0.0001$ ) (Figure). Further analysis of the 18 seropositive samples with a  
61 multiplex bead-based assay that detects antibody isotype reactivity to RBD, S and N proteins (5)  
62 revealed a pattern consistent with infections that occurred weeks or months prior; a dominance of  
63 RBD and S protein IgG with few samples positive for N protein IgG, nor IgA or IgM against any  
64 of the three antigens (Figure). Within these 18 seropositive samples, six were retrospectively  
65 matched to donors with previously confirmed SARS-CoV-2 infections. That all confirmed cases  
66 were detected supports the rationale of the testing algorithm applied. A further four seropositive

67 samples were from donors with 2020 travel history in settings with a high risk of SARS-CoV-2  
68 exposure (United Kingdom and Europe), suggesting likely infection outside New Zealand. The  
69 remaining eight seropositive samples were from seven different district health regions, giving a  
70 crude seroprevalence estimate of 0.082% (95% confidence intervals [CI] 0.035-0.16%). Applying  
71 the Rogan-Gladen estimate with the Lang-Reiczigel CI method to account for test sensitivity and  
72 specificity results in a true seroprevalence estimate of 0.103% (95% CI 0.09-0.12%) (Appendix)  
73 and an infection to case ratio of 2.3, based on notified cases on January 6<sup>th</sup>, 2021, suggesting some  
74 undiagnosed infections have occurred. However, this ratio needs to be interpreted with caution  
75 given the limitations of the sampling population, together with the extremely low number of  
76 seropositive donors, which also precludes any subgroup analysis.

77         The very low seroprevalence of SARS-CoV-2 infection in New Zealand implies undetected  
78 community transmission has been limited. This seroprevalence is broadly similar to a recent study  
79 conducted in a low prevalence state of Australia (3), and markedly lower than estimates of >10%  
80 from serosurveys in Europe and America where the pandemic has been poorly controlled  
81 (<https://serotracker.com>). This study provides the first robust, serological evidence of New  
82 Zealand's successful elimination strategy ahead of vaccine roll-out.

83

## 84 **Acknowledgments**

85         This work was funded by the School of Medicine Foundation (University of Auckland),  
86 and the COVID-19 Innovation Acceleration Fund (Ministry of Business, Innovation and  
87 Employment). The 2018 Census data used in this study were supplied by Statistics New Zealand  
88 (Stats NZ) and accessed via its Integrated Data Infrastructure (IDI).

## 89 **Statistics New Zealand Disclaimer**

90 Access to the data used in this study was provided by Stats NZ under conditions designed to give  
91 effect to the security and confidentiality provisions of the Statistics Act 1975. The results presented  
92 in this study are the work of the author, not Stats NZ or individual data suppliers.

93

## 94 **References**

- 95 1. Baker MG, MBChB NW, Anglemyer A. Successful Elimination of Covid-19  
96 Transmission in New Zealand. *N Engl J Med*. 2020 Aug 7;1–3.
- 97 2. Uyoga S, Adetifa IMO, Karanja HK, Nyagwange J, Tuju J, Wanjiku P, et al.  
98 Seroprevalence of anti-SARS-CoV-2 IgG antibodies in Kenyan blood donors.  
99 *Science*. 2021 Jan 1;371(6524):79–82.
- 100 3. Gidding HF, Machalek DA, Hendry A, et al. Seroprevalence of SARS-CoV-2-  
101 specific antibodies in Sydney, Australia following the first epidemic wave in 2020.  
102 *The Medical Journal of Australia*, *preprint*.
- 103 4. Geoghegan JL, Moreland NJ, Gros G, Ussher JE. New Zealand’s science-led  
104 response to the SARS-CoV-2 pandemic. *Nat Immunol*. Springer US; 2021 Feb  
105 20;1–2.
- 106 5. Whitcombe AL, McGregor R, Craigie A, James A, Charlewood R, Lorenz N, et al.  
107 Comprehensive analysis of SARS-CoV-2 antibody dynamics in New Zealand. *Clin*  
108 *Transl Immunology*. 2021;10(3):e1261.
- 109 6. Carvalho T, Krammer F, Iwasaki A. The first 12 months of COVID-19: a timeline  
110 of immunological insights. *Nature reviews Immunology*. 2021 Mar 15;1–12.
- 111 7. Bond K, Nicholson S, Lim SM, Karapanagiotidis T, Williams E, Johnson D, et al.  
112 Evaluation of serological tests for SARS-CoV-2: Implications for serology testing in  
113 a low-prevalence setting. *J INFECT DIS*. 2020 Aug 6.

- 114 8. Amanat F, Stadlbauer D, Strohmeier S, Nguyen THO, Chromikova V, McMahon M,  
115 et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. Nat  
116 Med. 2020 May 12;5:562–12.
- 117 9. McGregor R, Whitcombe AL, Sheen CR, Dickson JM, Day CL, Carlton LH, et al.  
118 Collaborative networks enable the rapid establishment of serological assays for  
119 SARS-CoV-2 during nationwide lockdown in New Zealand. PeerJ.  
120 2020;8(19):e9863.
- 121 10. Craigie A, McGregor R, Whitcombe A, Carlton L, Harte D, Sutherland M, et al.  
122 SARS-CoV-2 antibodies in the Southern Region of New Zealand. Pathology -  
123 Journal of the RCPA (in press).

124

125 **Table. Demographics of the blood donors, 2018 Census population and COVID-19 cases in**  
126 **New Zealand.** The New Zealand blood service donations were collected between the 3<sup>rd</sup> of  
127 December 2020 and the 6<sup>th</sup> of January 2021. Of the 9,806 individuals, 9,771 are blood donors and  
128 35 are living tissue and stem cell donors. All donors must be free of illness and weigh >50 kg.  
129 Notable travel and a history SARS-CoV-2 infection (or contact with a positive case) are recorded  
130 prior to collection. Demographics for COVID-19 cases were obtained from the New Zealand  
131 Ministry of Health and includes probable and confirmed infections up to and including the 6<sup>th</sup> of  
132 January 2021. The most recent New Zealand census took place in March 2018. Priority ethnicity  
133 is reported as defined by the New Zealand Department of Statistics. Abbreviations: MELAA,  
134 Middle Eastern, Latin American and African; DHB, District Health Board; MIQ, Managed  
135 Isolation and Quarantine.

136



		Blood Donors		2018 Census Population		COVID-19 cases	
		n	%	n	%	n	%
<b>Total</b>		9,806	100.00%	4,793,361	100.00%	2,190	100.00%
<b>Sex</b>	<b>Male</b>	4,990	50.89%	2,364,315	49.30%	1,037	47.35%
	<b>Female</b>	4,816	49.11%	2,429,046	50.70%	1,153	52.65%
<b>Prioritised Ethnicity</b>	<b>Maori</b>	710	7.24%	777,195	16.20%	192	8.77%
	<b>Pacific Island</b>	192	1.96%	314,202	6.60%	184	8.40%
	<b>Asian</b>	921	9.39%	705,384	14.70%	393	17.95%
	<b>MELAA</b>	144	1.47%	68,283	1.40%	73	3.33%
	<b>European/Other*</b>	7,631	77.82%	2,924,175	61.00%	1,337	61.05%
	<b>Unknown</b>	208	2.12%	4,122	0.10%	11	0.50%
<b>Age</b>	<b>0-14 years</b>	0	0.00%	927,102	19.34%	177	8.08%
	<b>15-19 years<sup>+</sup></b>	238	2.43%	308,304	6.40%	110	5.02%
	<b>20-29 years</b>	1,754	17.89%	681,963	14.20%	520	23.76%
	<b>30-39 years</b>	1,870	19.07%	624,363	13.00%	398	18.14%
	<b>40-49 years</b>	2,053	20.94%	619,641	12.90%	309	14.12%
	<b>50-59 years</b>	2,196	22.39%	623,445	13.00%	320	14.62%
	<b>60-69 years</b>	1,437	14.65%	510,327	10.60%	222	10.14%
	<b>70+ years</b>	258	2.63%	498,216	10.40%	134	6.12%
<b>DHB</b>	<b>Northland</b>	200	2.04%	179,007	3.70%	28	1.28%
	<b>Auckland</b>	1,478	15.07%	467,595	9.80%	226	10.32%
	<b>Waitemata</b>	613	6.25%	586,329	12.20%	297	13.57%
	<b>Counties</b>	494	5.04%	537,633	11.20%	217	9.91%
	<b>Waikato</b>	1,096	11.18%	405,555	8.50%	194	8.86%
	<b>Taranaki</b>	285	2.91%	117,684	2.50%	16	0.73%
	<b>Lakes</b>	282	2.88%	109,080	2.30%	16	0.73%
	<b>Bay of Plenty</b>	550	5.61%	240,117	5.00%	48	2.19%
	<b>Tairāwhiti</b>	0	0.00%	47,520	1.00%	4	0.18%
	<b>Hawkes Bay</b>	51	0.52%	166,287	3.50%	44	2.01%
	<b>Mid central</b>	792	8.08%	174,993	3.70%	32	1.46%
	<b>Whanganui</b>	0	0.00%	64,599	1.30%	9	0.41%
	<b>Wairarapa</b>	51	0.52%	45,327	0.90%	8	0.37%
	<b>Hutt Valley</b>	214	2.18%	148,509	3.10%	24	1.10%
	<b>Capital and Coast</b>	1,082	11.03%	303,957	6.30%	96	4.39%
	<b>Nelson Marlborough</b>	0	0.00%	150,528	3.10%	49	2.24%
	<b>West Coast</b>	0	0.00%	31,578	0.70%	5	0.23%
	<b>Canterbury</b>	1,774	18.09%	539,628	11.30%	168	7.67%
	<b>South Canterbury</b>	113	1.15%	58,977	1.20%	17	0.78%
	<b>Southern</b>	731	7.45%	324,387	6.80%	216	9.87%
<b>Unknown</b>	0	0.00%	94,071	2.00%	0	0.00%	
<b>MIQ</b>	-	0	0.00%	0	0.00%	476	21.70%

\* 'Other' comprises of n=28 (0.20%) of the blood donor population, and n= 51,447 (1.10%) of the New Zealand census population.

<sup>+</sup> All blood donors are at least 16 years of age.

137  
138  
139  
140

141

142 **Figure. Antibody characteristics of the seropositive donors (n=18).** (a) Seropositivity was  
 143 confirmed by EuroImmun S1 IgG (top) and the surrogate Viral Neutralization Test (sVNT,  
 144 bottom). Six donors had PCR confirmed SARS-CoV-2 infection (dark grey), four had relevant  
 145 travel history (dark turquoise), and eight were identified in this study (orange). The manufacturers  
 146 cut-offs are shown (black dotted line). (b) Pearson correlation of sVNT and the Euroimmun IgG  
 147 ELISA (n=18). (c) Rose plot showing percentage of seropositive donors over baseline for IgG,  
 148 IgA and IgM antibodies against the RBD, Spike (S) and Nucleocapsid (N) proteins determine  
 149 using a multi-plex Luminex bead assay.

